OncoMatch/Clinical Trials/NCT04329728
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Is NCT04329728 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies AVM0703 for lymphoid malignancies.
Treatment: AVM0703 — This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Must have received: autologous hematopoietic cell transplant — relapsed/refractory
R/R after autologous hematopoietic cell transplant (HCT)
Must have received: CAR-T cell therapy — relapsed/refractory
R/R after chimeric antigen receptor T-cell (CAR T) therapy
Must have received: anti-CD20 antibody — relapsed/refractory
R/R after ≥2 lines of therapy including anti-CD20 antibody and failed, intolerant or ineligible for polatuzamab vedotin
Must have received: Bruton's tyrosine kinase (BTK) inhibitor (acalabrutinib) — relapsed/refractory
failed acalabrutinib or be R/R after ≥2 lines of therapy including at least 1 of the following: a Bruton's tyrosine kinase (BTK) inhibitor, bortezomib, or lenalidomide
Must have received: bortezomib (bortezomib) — relapsed/refractory
R/R after ≥2 lines of therapy including at least 1 of the following: a Bruton's tyrosine kinase (BTK) inhibitor, bortezomib, or lenalidomide
Must have received: lenalidomide (lenalidomide) — relapsed/refractory
R/R after ≥2 lines of therapy including at least 1 of the following: a Bruton's tyrosine kinase (BTK) inhibitor, bortezomib, or lenalidomide
Must have received: methotrexate (methotrexate) — relapsed/refractory
R/R after ≥1 line of therapy including methotrexate (unless intolerant to methotrexate)
Must have received: venetoclax (venetoclax) — relapsed/refractory
R/R after ≥2 lines of therapy including at least 1 of the following: a BTK inhibitor, venetoclax, idelalisib, or duvelisib
Must have received: idelalisib (idelalisib) — relapsed/refractory
R/R after ≥2 lines of therapy including at least 1 of the following: a BTK inhibitor, venetoclax, idelalisib, or duvelisib
Must have received: duvelisib (duvelisib) — relapsed/refractory
R/R after ≥2 lines of therapy including at least 1 of the following: a BTK inhibitor, venetoclax, idelalisib, or duvelisib
Must have received: allogeneic hematopoietic cell transplant — relapsed/refractory
R/R after allogeneic HCT
Must have received: inotuzumab ozogamicin (inotuzumab ozogamicin) — relapsed/refractory
≥2 lines of therapy including approved CAR T cell therapies, inotuzumab ozogamicin, or blinatumomab
Must have received: blinatumomab (blinatumomab) — relapsed/refractory
≥2 lines of therapy including approved CAR T cell therapies, inotuzumab ozogamicin, or blinatumomab
Must have received: nelarabine (nelarabine) — relapsed/refractory
≥2 lines of therapy including nelarabine
Lab requirements
Blood counts
Absolute neutrophil count ≥0.05 × 10^9/L; Platelet count ≥25 × 10^9/L; Hemoglobin ≥6.5 g/dL
Kidney function
Glomerular filtration rate ≥30 mL/min; except for patients on metformin at baseline GFR must be ≥45 mL/min
Liver function
Aspartate aminotransferase or alanine aminotransferase ≥2.5 × ULN, unless due to the disease; Total bilirubin <1.5 × ULN (if secondary to Gilbert's syndrome, <3 × ULN is permitted), unless due to the disease
Cardiac function
Minimum level of pulmonary reserve defined as <Grade 2 dyspnea and pulse oximetry ≥92% on room air
Screening laboratory values that meet all of the following criteria: ... Minimum level of pulmonary reserve defined as <Grade 2 dyspnea and pulse oximetry ≥92% on room air
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- Los Angeles Cancer Network · Los Angeles, California
- UCLA Medical Center of Hematology/Oncology · Los Angeles, California
- Innovative Clinical Research Institute · Whittier, California
- ASCLEPES Research Centers · Weeki Wachee, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify